InvestorsHub Logo
Followers 840
Posts 120476
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Friday, 12/03/2021 9:08:46 AM

Friday, December 03, 2021 9:08:46 AM

Post# of 1169
Reblozyl sBLA in beta thalassemia—>3/27/22 PDUFA date—(with FDA priority review):

https://www.businesswire.com/news/home/20211203005095/en

BMY is now partnered with MRK on Reblozyl development and commercialization as a result of MRK’s buyout of XLRN, which makes for an odd working relationship.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News